WilmerHale Represents Nuvalent in Public Offering
On October 19, 2023, Nuvalent, Inc., a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer,
announced the closing of its underwritten public offering of 5,357,143 shares of its Class A common stock, at a price to the public of $56.00 per share. The aggregate gross proceeds to Nuvalent were $281.6 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Nuvalent. J.P. Morgan Securities LLC, Cowen and Company, LLC, Piper Sandler & Co. and BMO Capital Markets Corp. acted as joint book-running managers for the offering. Wedbush Securities Inc. acted as a manager for the offering.
The WilmerHale team advising Nuvalent in its public offering was led by
Cynthia Mazareas,
Andrea Sorrentino,
Katharine Patterson,
Matt Kosior and
AJ Febles, with assistance from
Julie Hogan Rogers,
Bruce Manheim,
Ben Lobley,
Heidi Treiber and Senior Paralegal Mark Devine.
